TCON

TRACON Pharmaceuticals, Inc.

1.09 USD
+0.09 (+9.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TRACON Pharmaceuticals, Inc. stock is down -44.67% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 June’s closed higher than May.

About TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody. TRC102, a small molecule that is in Phase II clinical trial for the. treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and gliob